MedTrace Logo

Adenosine vs Diltiazem for Treatment of SVT in the ED

NCT06993038 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-11

No results posted yet for this study

Summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Conditions

  • Supraventricular Tachycardia (SVT)

Interventions

DRUG

adenosine

IV adenosine at standard doses for SVT (6 mg, 12 mg)

DRUG

diltiazem

IV diltiazem at standard doses for SVT (0.25 mg/kg)

Sponsors & Collaborators

  • Anne E. Zepeski

    lead OTHER

Principal Investigators

  • Anne Zepeski, PharmD · University of Iowa

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-01
Primary Completion
2026-07-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06993038 on ClinicalTrials.gov